Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 250,728 | 22,196 | 23,694 | 23,787 | 19,137 |
| Marketable Securities | 160,915 | 67,338 | 57,539 | 103,639 | 85,629 |
| Receivables | 19,064 | 2,032 | 4,055 | 6,490 | 16,570 |
| TOTAL | $471,171 | $94,201 | $87,815 | $138,362 | $124,597 |
| Non-Current Assets | |||||
| PPE Net | 11,348 | 12,773 | 15,949 | 18,320 | 9,025 |
| Investments And Advances | 4,895 | 6,315 | 9,406 | 11,395 | 19,830 |
| Intangibles | 13,660 | 14,207 | 15,274 | 16,523 | 18,142 |
| Other Non-Current Assets | 38,699 | 16,455 | 2,670 | 2,639 | 2,113 |
| TOTAL | $68,602 | $49,751 | $43,298 | $48,877 | $49,110 |
| Total Assets | $539,773 | $143,952 | $131,113 | $187,239 | $173,707 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 21,847 | 18,967 | 24,113 | 24,206 | 20,670 |
| Accrued Expenses | 9,950 | 4,050 | 5,672 | 8,612 | 6,368 |
| Other current liabilities | N/A | N/A | N/A | 361 | 1,168 |
| TOTAL | $41,706 | $31,989 | $35,300 | $35,405 | $43,823 |
| Non-Current Liabilities | |||||
| Long Term Debt | 4,516 | 12,843 | N/A | N/A | N/A |
| Deferred Revenues | 7,579 | 6,898 | 5,516 | 2,227 | 15,617 |
| Other Non-Current Liabilities | 33,325 | 94,639 | 87 | 0 | 0 |
| TOTAL | $36,926 | $106,557 | $8,781 | $9,345 | $6,506 |
| Total Liabilities | $78,632 | $138,547 | $44,081 | $44,751 | $50,329 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 17,296 | 12,145 | 8,133 | 7,531 | 6,173 |
| Common Shares | 187 | 101 | 97 | 90 | 74 |
| Retained earnings | -906,197 | -739,786 | -620,427 | -523,356 | -434,838 |
| Other shareholders' equity | -256 | 2,442 | -433 | -21 | 1,424 |
| TOTAL | $461,141 | $5,405 | $87,032 | $142,489 | $123,378 |
| Total Liabilities And Equity | $539,772 | $143,952 | $131,113 | $187,239 | $173,707 |